Loss of ambulation increases FA patient management costs from both NHS and societal perspectives.
Monday, November 16, 2026
EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status
Ippazio Cosimo Antonazzo, Paolo Angelo Cortesi, Lorenzo G. Mantovani, Richard Lawson, Leila Khader, Claudia Oliviero, Laura Santoni, Antonio Cittadini, Gabriella Paparella, Francesco SaccĂ , EE497 Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status, Value in Health, Volume 28, Issue 12, Supplement 1, 2025, Pages S203-S204, ISSN 1098-3015, doi:10.1016/j.jval.2025.09.879.
Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation
Zhou, J., Ma, X., Jiang, B. et al. Omaveloxolone functions as a molecular crowbar-like degrader of STING to alleviate aging-related inflammation. Nat Commun 17, 11202 (2026). doi:10.1038/s41467-026-77760-1
Aberrant activation of the STING signaling pathway is involved with aging-related inflammation, yet no STING-targeting therapeutics are clinically approved. Here, we identify Omaveloxolone, an FDA-approved drug for Friedreich’s ataxia, as a potent STING degrader (DC50 = 118 nM, Dmax = 98.6%) via high-throughput screening.
This study implicates Omaveloxolone as a molecular crowbar-like STING degrader and provides a mechanistic framework for targeting STING via conformational perturbation.
Larimar Narrows Q3 Loss; Completes BLA Submission For Nomlabofusp In Friedreich's Ataxia
Published: 11/16/2026. Larimar completed its rolling BLA submission to the U.S. Food and Drug Administration (FDA), seeking accelerated approval of nomlabofusp for adults and pediatric patients with Friedreich's ataxia. The application uses frataxin (FXN) as a potential novel surrogate endpoint.
BLA submission acceptance is expected in early 2027. An open-label study safety update is anticipated in the first quarter of 2027, followed by a potential U.S. approval in mid-2027, subject to FDA review.
If approved, Larimar is targeting a U.S. commercial launch in the third quarter of 2027. The company also expects to obtain and monetize a Rare Pediatric Disease Priority Review Voucher in mid-2027, if nomlabofusp receives approval.
Subscribe to:
Posts (Atom)
